Skip to main content
Beni-Suef University Journal of Basic and Applied Sciences

Table 1 Summary of the studies for the IOP between HRT-treated patients and the control subjects

From: The association of estrogen-signaling pathways and susceptibility to open-angle glaucoma

Author

Country

Mean age (year)

Duration of treatment

Type

IOP (mmHg)

HRT

non-HRT/pre

n

Mean

SD

n

Mean

SD

Abramov et al. 2005 (a) [20]

Israel

66.45

12ā€‰months

NA (RO)

107

15.2

0.4

107

15.5

0.4

Abramov et al. 2005 (b)

NA (LO)

107

15.3

0.5

107

15.2

0.2

Affinito et al. 2003 (a) [21]

Italy

53.7

3ā€‰months

Estradiol + medroxyprogesterone acetate

24

14.1

2

24

16.6

2.3

Affinito et al. 2003 (b)

6ā€‰months

24

14.1

2.1

24

16.6

2.4

Altintaş et al. 2004 (a) [22]

Turkey

46.1

2ā€‰months

NA

20

12.33

1.76

24

14.66

1.71

Altintaş et al. 2004 (b)

20

12.33

1.76

20

16.16

2.32

Coksuer et al. 2011 [23]

Turkey

45ā€“60*

6ā€‰months

Estradiol + drospirenone

34

13.4

2.7

34

14.1

2.8

Guaschino et al. 2003 [24]

Italy

59.9

12ā€‰months

Estradiol + dydrogesterone

40

14.8

3.2

40

14.9

4.3

Ɩzcan et al. 2017 (a) [25]

Turkey

49.9

6ā€‰months

NA

61

13.9344

1.47

76

15.41

1.76

Ɩzcan et al. 2017 (b)

61

13.9344

1.47

76

14.35

1.4

Sator et al. 1997 (a) [26]

Austria

55.7

1ā€‰week

Estradiol + medroxyprogesterone acetate (RO)

25

14.9

2

25

15.2

2.6

Sator et al. 1997 (b)

Estradiol + medroxyprogesterone acetate (LO)

25

15.2

2.4

25

15.9

2.6

Sator et al. 1997 (c)

1ā€‰month

Estradiol + medroxyprogesterone acetate (RO)

25

14.4

2.1

25

15.2

2.6

Sator et al. 1997 (d)

Estradiol + medroxyprogesterone acetate (LO)

25

14.2

2.3

25

15.9

2,6

Sator et al. 1997 (e)

3ā€‰months

Estradiol + medroxyprogesterone acetate (RO)

25

13.8

1.9

25

15.2

2.6

Sator et al. 1997 (f)

Estradiol + medroxyprogesterone acetate (LO)

25

14.2

2.3

25

15.9

2.6

Tint et al. 2010 (a) [27]

Scotland

59.35

NA

Estradiol only

33

11.81

2.91

172

13.25

2.85

Tint et al. 2010 (b)

Combined

58

11.87

2.51

172

13.25

2.85

Toker et al. 2003 [28]

Turkey

52.4

1.5ā€‰months

NA

30

13.29

2.28

32

13.56

2.5

Vajaranant et al. 2016 (a) [29]

USA

71.875

5 Ā± 1ā€‰years

Estradiol (RO)

808

15.4

3.2

860

15.8

3.3

Vajaranant et al. 2016 (b)

Estradiol + progestin (RO)

1397

15.6

3

1282

15.7

3.1

Vajaranant et al. 2016 (c)

Estradiol (LO)

808

15.3

3.1

860

15.9

3.2

Vajaranant et al. 2016 (d)

Estradiol + progestin (LO)

1397

15.7

3

1282

15.7

3

  1. n and SD represented the number of samples and standard deviation of IOP, respectively
  2. NA not available, RO right ocular, LO left ocular
  3. *Data presented as range
Back to article page